"ITL will retain a strong presence in Australia, including an...

"ITL will retain a strong presence in Australia, including an extensive sales and distribution network across the country. ITL will retain ownership of business units that manufacture and sell the following products, that together contributed $8.9m in the last financial year: • Invasive blood pressure monitoring kits (sold in 46 hospitals in Australia);

• Class 3 Intra Venous (IV) starter packs; and • Numerous sponsored products.
• Invasive blood pressure monitoring kits (sold in 46 hospitals in Australia); • "

This is the segment that will remain with ITD with annual revenue of 8.9 m, The part that deals with blood which is the profitable higher margin segment. WELL DONE as they become cash positive with 10 million to accelerate growth. money is key to investment and growth and is normally a huge obstacle for small companies.

ITD can now concentrate on global expansion of ITL BioMedical products, the company already have a low-cost manufacturing plant in Malaysia. Quality diverse and specialized products with IP in place.
Now to the global expansion and further product development.

This is what ITL does best so why not concentrate and accelerate this high-profit margin segment.